hsa-miR-133b

ncRNA information

ncRNA name

hsa-miR-133b

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

None

Biomarker application

Upstream regulatory factors

Not available

Downstream target

FGFR1

Cancer information

Cancer name

Triple-Negative Breast Cancer

Cancer site

qRT-PCR,Western blot,Dual-luciferase assay

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Down

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

miR-133b can inhibit the growth and DDP resistance of TNBC cells by targeting FGFR1 and inactivating the Wnt-Ī²-catenin pathway

Tissue resource

breast cancer tissues and adjacent tissues

human normal mammary epithelial cells MCF-10A

triple-negative breast cancer cell lines MDA-MB-468

triple-negative breast cancer cell lines HCC1395

Experiment

None


Institute

Affiliated Hospital of Southwest Medical University

Otwo Biotech Inc

Country

China

China

Continent

Asia

Asia